Vertex Pharma (VRTX) Tops Q1 EPS by 14c, Misses on Revenue; Offers FY26 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mail
Get Alerts VRTX Hot Sheet
Price: $558.88 --0%
Revenue Growth %: +10.7%
Financial Fact:
Net loss attributable to noncontrolling interest (Alios): 696K
Today's EPS Names:
AES, SYRS, ZVOI, More
Revenue Growth %: +10.7%
Financial Fact:
Net loss attributable to noncontrolling interest (Alios): 696K
Today's EPS Names:
AES, SYRS, ZVOI, More
Join SI Premium – FREE
Vertex Pharma (NASDAQ: VRTX) reported Q1 EPS of $4.47, $0.14 better than the analyst estimate of $4.33. Revenue for the quarter came in at $2.99 billion versus the consensus estimate of $3.03 billion.
GUIDANCE:
Vertex Pharma sees FY2026 revenue of $12.95-13.1 billion, versus the consensus of $13.05 billion.
For earnings history and earnings-related data on Vertex Pharma (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tower Semiconductor (TSEM) Misses Q3 EPS by 1c ; Offers Guidance
- CorMedix reaffirms 2026 revenue guidance, reports $355M cash
- Seaport Therapeutics, Inc. (SPTX) Misses Q3 EPS by 49c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
